NASDAQ:OCDX

Ortho Clinical Diagnostics (OCDX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$17.63
$17.63
50-Day Range
$17.63
$17.63
52-Week Range
$16.04
$22.99
Volume
5,400 shs
Average Volume
1.24 million shs
Market Capitalization
$3.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OCDX stock logo

About Ortho Clinical Diagnostics Stock (NASDAQ:OCDX)

Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.

OCDX Stock News Headlines

Novacyt: Innovative Clinical Diagnostics
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
See More Headlines
Receive OCDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ortho Clinical Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
NASDAQ:OCDX
Fax
N/A
Employees
4,800
Year Founded
N/A

Profitability

Net Income
$-54,300,000.00
Pretax Margin
1.38%

Debt

Sales & Book Value

Annual Sales
$2.04 billion
Cash Flow
$2.28 per share
Book Value
$1.99 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.92 billion
Optionable
Not Optionable
Beta
1.32
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives


OCDX Stock Analysis - Frequently Asked Questions

How were Ortho Clinical Diagnostics' earnings last quarter?

Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) released its earnings results on Wednesday, November, 3rd. The company reported $0.21 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.07. The firm had revenue of $522.50 million for the quarter, compared to the consensus estimate of $485.36 million. Ortho Clinical Diagnostics had a negative net margin of 0.02% and a positive trailing twelve-month return on equity of 41.71%.

When did Ortho Clinical Diagnostics IPO?

Ortho Clinical Diagnostics (OCDX) raised $1.5 billion in an initial public offering on Thursday, January 28th 2021. The company issued 70,000,000 shares at a price of $20.00-$23.00 per share. J.P. Morgan, BofA Securities, Goldman Sachs, Barclays and Morgan Stanley acted as the underwriters for the IPO and Citigroup, Credit Suisse, UBS Investment Bank, Evercore ISI, Piper Sandler, ING, Macquarie Capital, Nomura, TCG Capital Markets, Drexel Hamilton, H.C. Wainwright & Co., Ramirez & Co. and Siebert Williams Shank were co-managers.

This page (NASDAQ:OCDX) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners